ReviewTherapeutic advances in musculoskeletal disease2022
Osteosarcopenia and Long-COVID: a dangerous combination.
Review in Therapeutic advances in musculoskeletal disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Trolox, r-irisin and resveratrol cocktail to counteract osteoblast metabolism alterations in osteoarthritis and osteoporosis.Journal of bone and mineral metabolism · 2025Article
- Article
- A multidisciplinary review of long COVID to address the challenges in diagnosis and updated management guidelines.Annals of medicine and surgery (2012) · 2025Review
- Osteosarcopenia: epidemiology, molecular mechanisms, and management.Frontiers in endocrinology · 2025Review
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025Article
- The impact of osteosarcopenia and its parameters on mortality of COVID-19 in-hospitalized older patients: the findings of BEH (Bushehr elderly health) program.Journal of diabetes and metabolic disorders · 2024Article
- Improving quality in adult long covid services: Findings from the LOCOMOTION quality improvement collaborative.Clinical medicine (London, England) · 2024Article
- Article
- Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement.International journal of molecular sciences · 2024Review
- Self-managing symptoms of Long COVID: an education and strategies research protocol.Frontiers in public health · 2024Article
- Sarcopenia and Osteoporosis.Indian journal of orthopaedics · 2023Review
- Professional Athletes Maintain High TNF-Alpha or IFN-Gamma Related Inflammatory Status after Recovering from COVID-19 Infection without Developing a Neutralizing Antibody Response.Sports (Basel, Switzerland) · 2023Article
- Musculoskeletal involvement: COVID-19 and post COVID 19.Turkish journal of physical medicine and rehabilitation · 2023Review
- Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches.Journal of personalized medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 has caused a global pandemic and an unprecedented public health crisis, infecting more than 580 million people worldwide. Moreover, recent evidence has suggested the emergence of a new syndrome known as Long-COVID, a term used to describe a diverse set of physical and mental symptoms that persist after a diagnosed SARS-CoV-2 infection. Epidemiological data have identified myalgias, muscle and joint dysfunction, and bone fragility as common sequelae in patients with moderate and severe forms of this disease. Significant musculoskeletal dysfunction has also been detected in some healed patients, although knowledge about pathophysiological mechanisms of Long-COVID is still rather scarce. In this context, SARS-CoV-2 infection has been suggested to amplify the effects of aging on the musculoskeletal system by aggravating the osteosarcopenic state. Based on this evidence, our review focused on the muscle and bone tissue alterations induced by SARS-CoV-2 infection and Long-COVID, summarizing the current knowledge on the underlying biological mechanisms and highlighting the need for a multidisciplinary approach to predict the musculoskeletal targets and long-term consequences of COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.